This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
BPC-157 (5 mg Vial)
BPC-157 is a synthetic 15-amino-acid peptide investigated in experimental research. This overview summarizes cited studies and their limitations; it does not provide instructions for human use.
Quick Reference
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide investigated in experimental research. This overview summarizes cited studies and their limitations; it does not provide instructions for human use.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is BPC-157 studied?
BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein[2]. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues[1][3]. Experiments using rat tendon explants and cultured tendon fibroblasts reported increased tissue outgrowth and cell migration[6]. These laboratory observations do not demonstrate treatment efficacy in people. A Phase I oral safety trial has been completed[9], and a small human case series reported improvements following intra-articular administration[5]; however, large-scale controlled human efficacy data are not yet available.
What does the research report about BPC-157?
Observations from preclinical and early clinical literature.
• Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data)[1][3].
• Rat-derived tendon-cell experiments reported improved cell survival during oxidative stress[6]. This is laboratory evidence.
• Phase I safety studies report good tolerability with no serious adverse events at tested doses[9].
• Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
• Reference [4] reviews experimental research; it does not establish long-term safety or clinical effectiveness in humans.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on BPC-157?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
